Tigilanol tiglate preclinical data published in Journal for ImmunoTherapy of Cancer

3 May 2024

QBiotics Group Limited (QBiotics) is pleased to announce that a preclinical study on its lead intratumoural oncology asset, tigilanol tiglate, has been published in the prestigious Journal for ImmunoTherapy of Cancer.

The paper sheds further light on the mode of action of tigilanol tiglate, especially its immunomodulatory role in the treatment of solid tumours.

The results confirm that tigilanol tiglate acts via multiple pathways to promote tumour ablation and may also effectively control disease burden in the right tumour (immunogenic) and patient contexts. In addition, tigilanol tiglate may also help augment the benefits of immunotherapy in clinical practice, especially in patients who do not initially respond to checkpoint inhibition.

Paper overview

Paper title:  Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.
Authors: Jason K Cullen, Pei-Yi Yap, Blake Ferguson, Zara C Bruce, Motoko Koyama, Herlina Handoko, Kevin Hendrawan, Jacinta L Simmons, Kelly M Brooks, Jenny Johns, Emily S Wilson, Marjorie M A de Souza, Natasa Broit, Praphaporn Stewart, Daniel Shelley, Tracey McMahon, Steven M Ogbourne, Tam Hong Nguyen, Yi Chieh Lim, Alberto Pagani, Giovanni Appendino, Victoria A Gordon, Paul W Reddell, Glen M Boyle, Peter G Parsons
Journal: Journal for ImmunoTherapy of Cancer 2024 12:e006602
DOI: https://doi.org/10.1136/jitc-2022-006602